UK - SV Life Sciences appoints new venture partner

Cameron will be based in the firm's London office and will focus on therapeutic investments in both Europe and the United States. He joins the firm following a period as CEO of Cambridge Antibody Technology, a position he took up in 2006 following the acquisition of the firm by AstraZeneca, where he had previously held a series of senior positions. He began his career as a physician in the UK before beginning his industry career with Janssen.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• People
• UK / Ireland